epalrestat的新型作用:通过向阿尔多减少酶,防止NLRP3炎症酶驱动的NASH
Wei Shi1,2,3, Guang Xu4, Yuan Gao3
1School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
Journal of translational medicine
|October 7, 2023
概括
阿尔多缩酶抑制剂Epalrestat有效抑制NLRP3炎症酶激活,为非酒精性脂肪肝炎 (NASH) 提供了潜在的新疗法. 这种药物在缓解肝炎和改善临床前模型中NASH病理学方面表现有前途.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 非酒精性脂肪肝炎 (NASH) 是一种进展性肝病,治疗选择有限.
- 炎症和纤维化是NASH的特征,超过20%的病例进展为肝硬化.
- 目前的治疗方法,包括减肥,往往无法显著改善肝脏组织学.
研究的目的:
- 为了调查epalrestat作为NASH的潜在治疗剂.
- 阐明epalrestat影响炎症酶激活的机制.
- 评估epalrestat在临床前NASH模型中的疗效和安全性.
主要方法:
- 使用BMDM和THP1细胞构建了炎酶激活模型.
- 评估了epalrestat对NLRP3炎症酶激活的作用,使用西斑,qPCR,流细胞计和ELISA.
- 评估了epalrestat在食诱导的NASH模型中缺乏氨酸和胆 (MCD) 的治疗效果.
- 在小鼠中进行了14天的epalrestat安全性研究.
主要成果:
- 埃帕尔雷斯塔特通过准多缩酶在caspase-1上游的作用来抑制NLRP3炎症酶激活.
- 该药物在体内表现出有效性,减少肝炎并改善NASH病理.
- 在之前的研究中,Epalrestat被认为是临床有效和安全的.
结论:
- 作为阿尔多缩酶抑制剂的Epalrestat有效地抑制了NLRP3炎症酶激活,无论是体外还是体内.
- 埃帕尔雷斯塔特 (Epalrestat) 是一种有前途的新型治疗方法,用于治疗纳什.
- 需要对NASH治疗的epalrestat进行进一步的临床研究.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
934
08:35A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
Published on: May 18, 2021
6.4K
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
657
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
657
01:31Regulation of the Unfolded Protein Response
2.5K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
445
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
445
01:37The Unfolded Protein Response
4.7K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
4.7K
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
495
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
495
01:27Phase I Reactions: Reductive Reactions
214
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
214